Plasma levels of apolipoprotein-E in residents of the European North of Russia

Kaneva, Anastasiya M.; Bojko, Evgeny R.; Потолицына, Н. Н.; Odland, Jon Øyvind

doi:10.1186/1476-511x-12-43

Cited by 10 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, plasma ApoE levels were considered low, but comparable to those found in the study by Kaneva et al, where the shift in plasma ApoE toward lower levels in European residents as a result of specific features of lipid metabolism was demonstrated [ 32 ]. We also demonstrated the screening utility of maternal serum ApoE measurement as a potential noninvasive marker of DS.…”

Section: Discussionsupporting

confidence: 89%

The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome

Buczyńska

Sidorkiewicz

Ławicki

et al. 2020

JCM

View full text Add to dashboard Cite

Prenatal screening for Down syndrome (DS) is based on both noninvasive and invasive methods. Noninvasive, cell-free fetal DNA genetic tests are expensive, whereas biochemical methods remain imprecise. Amniocentesis is the most frequently used invasive diagnosis procedure, characterized by 99.8% diagnostic efficiency and less than 1% risk of miscarriage. The aim of this study was to evaluate the screening value of apolipoprotein E (ApoE) as a potential noninvasive biomarker for prenatal DS assessment. This study was conducted on a group of female patients who decided to undergo routine amniocentesis between the 15th and 18th week of pregnancy at the Department of Reproduction and Gynecological Endocrinology of the Medical University of Bialystok, Poland. For the purpose of this study, 20 women with DS fetuses were selected as the study group, and 20 healthy pregnant women with euploid fetus karyotypes as the control group. The plasma levels of ApoE were significantly higher in the study group compared to healthy subjects (p < 0.05). The area under the receiver operating characteristic (ROC) curve was 0.978 (p < 0.001), with the cut-off set to 1.37 mg/mL, which was characterized by 80% of sensitivity and 100% of specificity. The high sensitivity and specificity demonstrate the screening utility of maternal ApoE concentration in prenatal fetal DS screening.

show abstract

Section: Discussionsupporting

confidence: 89%

The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome

Buczyńska

Sidorkiewicz

Ławicki

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Accordingly, diverse studies have shown that Apo E −/− mice suffer hypercholesterolemia and an association between Apo E levels and CVD has also been reported in humans [ 51 , 52 ]. Even more, it has been shown that in the absence of some isoforms of Apo E, the beneficial cardioprotective effect of ω3 PUFA may be partially lost [ 53 , 54 ]. Of note, our results highlight an association between Apo E increase in LDL and an improved TG profile in obese subjects after four weeks intervention with ω3-milk.…”

Section: Discussionmentioning

confidence: 99%

Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study

Lambert¹,

Cubedo

Padró

et al. 2017

Nutrients

View full text Add to dashboard Cite

Cardiovascular disease (CVD) remains one of the major causes of death and disability worldwide. In addition to drug treatment, nutritional interventions or supplementations are becoming a health strategy for CVD prevention. Phytosterols (PhyS) are natural components that have been shown to reduce cholesterol levels; while poly-unsaturated fatty acids (PUFA), mainly omega-3 (ω3) fatty acids, have shown to reduce triglyceride levels. Here we aimed to investigate whether the proteins in the main lipoproteins (low density lipoproteins (LDL) and high density lipoproteins (HDL)) as well as proteins in the lipid free plasma fraction (LPDP) were regulated by the intake of PhyS-milk or ω3-milk, in overweight healthy volunteers by a proteomic based systems biology approach. The study was a longitudinal crossover trial, including thirty-two healthy volunteers with body mass index (BMI) 25–35 kg/m2 (Clinical Trial: ISRCTN78753338). Basal samples before any intervention and after 4 weeks of intake of PhyS or ω3-milk were analyzed. Proteomic profiling by two dimensional electrophoresis (2-DE) followed by mass spectrometry-(MALDI/TOF), ELISA, Western blot, conventional biochemical analysis, and in-silico bioinformatics were performed. The intake of PhyS-milk did not induce changes in the lipid associated plasma protein fraction, whereas ω3-milk significantly increased apolipoprotein (Apo)- E LDL content (p = 0.043) and induced a coordinated increase in several HDL-associated proteins, Apo A–I, lecitin cholesterol acyltransferase (LCAT), paraoxonase-1 (PON-1), Apo D, and Apo L1 (p < 0.05 for all). Interestingly, PhyS-milk intake induced a reduction in inflammatory molecules not seen after ω3-milk intake. Serum amyloid P component (SAP) was reduced in the LPDP protein fraction (p = 0.001) of subjects taking PhyS-milk and C-C motif chemokine 2 (CCL2)expression detected by reverse transcription polymerase chain reaction (RT-PCR) analysis in white blood cells was significantly reduced (p = 0.013). No changes were observed in the lipid-free plasma proteome with ω3-milk. Our study provides novel results and highlights that the PhyS-milk induces attenuation of the pro-inflammatory pathways, whereas ω3-milk induces improvement in lipid metabolic pathways.

show abstract

“…Too little apoE impairs the clearance of TG-rich lipoproteins and their remnants from plasma. Too much apoE stimulates very low-density lipoproteins production in the liver and impairs lipoprotein lipase-mediated lipolysis, leading to hypertriglyceridemia [ 43 , 44 ]. We have previously shown that the low apoE levels may contribute to hypertriglyceridemia in residents of the European North of Russia [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

et al. 2015

View full text Add to dashboard Cite

Background. The apolipoprotein (apo) B/apoA-I ratio represents the balance between apoB-rich atherogenic particles and apoA-I-rich antiatherogenic particles, and this ratio is considered to be a marker of cardiovascular risk. Although many studies have demonstrated the importance of the apoB/apoA-I ratio in predicting the presence or absence of cardiovascular disease, less is known about apoB/apoA-I ratio as a marker of plasma atherogenicity. Methods. A total of 157 normolipidemic men aged 20–59 years were included in the study. The plasma levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), apoA-I, apoB, and apoE were determined after a 12 h fasting period. Results. The median of the apoB/apoA-I ratio in the studied normolipidemic subjects was 0.52, with values ranging from 0.19 to 2.60. The percentage of subjects with the apoB/apoA-I ratio exceeding 0.9 (the accepted risk value of cardiovascular disease) was 19.1%. The subjects with apoB/apoA-I>0.9 were characterized by higher TG levels and atherogenic index of plasma (AIP) and lower values of ratio of low-density lipoprotein cholesterol (LDL-C) to apoB (LDL-C/apoB) and apoE levels compared with men with apoB/apoA-I<0.9. Conclusion. Despite normolipidemia, the subjects with the unfavorable apoB/apoA-I ratio had more atherogenic lipid profile.

show abstract

Plasma levels of apolipoprotein-E in residents of the European North of Russia

Cited by 10 publications

References 50 publications

The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome

The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome

Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

Contact Info

Product

Resources

About